183 related articles for article (PubMed ID: 34581647)
1. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
[TBL] [Abstract][Full Text] [Related]
2. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
Ren X; Yan C; Tian L; Cui X
Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
[TBL] [Abstract][Full Text] [Related]
3. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
6. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
[TBL] [Abstract][Full Text] [Related]
7. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
10. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
[TBL] [Abstract][Full Text] [Related]
12. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Gervaso L; Montero AJ; Jia X; Khorana AA
J Thromb Haemost; 2020 Jan; 18(1):162-168. PubMed ID: 31479568
[TBL] [Abstract][Full Text] [Related]
15. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Bachelot T
Breast Cancer; 2018 Jan; 25(1):17-27. PubMed ID: 29147869
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
19. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
